Amylyx announces common stock offering, no amount given
Pharmaceuticals announced that it has commenced an underwritten public offering of shares of its common stock. Amylyx intends to ...
FiercePharma4d
Amylyx names chief commercial officer as GLP-1 receptor antagonist launch plans start ramping up
Amylyx Pharmaceuticals has named Dan Monahan as chief commercial officer, positioning an exec who led the U.S.
BioSpace17h
HEALEY ALS Trial Serves Up More Disappointment as Denali, AbbVie/Calico Fail
Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...
FierceBiotech10h
Chutes & Ladders—Amylyx preps for GLP-1 launch with new CCO
Dan Monahan, the exec who led Otsuka’s commercialization of Rexulti and Abilify Maintena, is taking command of the launch of ...
STAT5h
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...
Why Is Amylyx Pharmaceuticals (AMLX) Among the Best Biotech Penny Stocks to Invest in Now?
We recently published a list of the 12 Best Biotech Penny Stocks To Invest In Now. In this article, we are going to take a ...
BioSpace3d
Denali Suffers Another ALS Fail With Phase II/III Flop
Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...
Nasdaq11d
Amylyx Partners with Gubra for GLP-1 Antagonist
Amylyx Pharmaceuticals Inc. has entered into a collaboration with Gubra A/S to develop a novel long-acting GLP-1 receptor antagonist. This partnership involves Amylyx making upfront and research ...
Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares are being ...